Vitamin D Reverses aPL-induced Inflammation and LMWH-induced sFlt-1 Release by Human Trophoblast

American Journal of Reproductive Immunology

Volumn 73, Issue 3, 2015, Pages 242-250

  Gysler, Stefan M ^a   Mulla, Melissa J ^a   Stuhlman, Meredith ^a   Sfakianaki, Anna K ^a   Paidas, Michael J ^a   Stanwood, Nancy L ^a   Gariepy, Aileen ^a   Brosens, Jan J ^b   Chamley, Lawrence W ^c   Abrahams, Vikki M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Angiogenic; Antiphospholipid antibody; Inflammation; Low molecular weight heparin; Trophoblast; Vitamin D

Indexed keywords

ANGIOGENIC FACTOR; CALCITRIOL; ENDOGLIN; ENOXAPARIN; INTERLEUKIN 1BETA; INTERLEUKIN 8; PHOSPHOLIPID ANTIBODY; PLACENTAL GROWTH FACTOR; SOLUBLE FMS LIKE TYROSINE KINASE 1; SOMATOMEDIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; ANTIINFLAMMATORY AGENT; CYTOKINE; FLT1 PROTEIN, HUMAN; IMMUNOGLOBULIN G; MEMBRANE PROTEIN; PIGF PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ARTICLE; CELL CULTURE; CELL FUNCTION; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INFLAMMATION; MOUSE; NONHUMAN; PLACENTA; PRIORITY JOURNAL; RISK REDUCTION; TROPHOBLAST; ANIMAL; CELL LINE; DRUG EFFECTS; IMMUNOLOGY; PRECLINICAL STUDY; PREGNANCY; SECRETION (PROCESS);

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, ANTIPHOSPHOLIPID; CALCITRIOL; CELL LINE; CYTOKINES; DRUG EVALUATION, PRECLINICAL; ENOXAPARIN; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION; INTERLEUKIN-8; MEMBRANE PROTEINS; MICE; PREGNANCY; TROPHOBLASTS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84922791456     PISSN: 10467408     EISSN: 16000897     Source Type: Journal    
DOI: 10.1111/aji.12301     Document Type: Article

References (70)

1. D'Cruz DP, Khamashta MA, Hughes GR: Systemic lupus erythematosus. Lancet 2007; 369:587-596.
2. Valesini G, Alessandri C: New facet of antiphospholipid antibodies. Ann N Y Acad Sci 2005; 1051:487-497.
3. de Laat B, Mertens K, de Groot PG: Mechanisms of disease: antiphospholipid antibodies-from clinical association to pathologic mechanism. Nat Clin Pract Rheumatol 2008; 4:192-199.
4. Di Simone N, Luigi MP, Marco D, Fiorella DN, Silvia D, Clara DM, Alessandro C: Pregnancies complicated with antiphospholipid syndrome: the pathogenic mechanism of antiphospholipid antibodies: a review of the literature. Ann N Y Acad Sci 2007; 1108:505-514.
5. Meroni PL, Borghi MO, Raschi E, Tedesco F: Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 2011; 7:330-339.
6. Oku K, Amengual O, Atsumi T: Pathophysiology of thrombosis and pregnancy morbidity in the antiphospholipid syndrome. Eur J Clin Invest 2012; 42:1126-1135.
7. Meroni PL, Raschi E, Grossi C, Pregnolato F, Trespidi L, Acaia B, Borghi MO: Obstetric and vascular APS: same autoantibodies but different diseases? Lupus 2012; 21:708-710.
8. Robertson SA, Roberts CT, van Beijering E, Pensa K, Sheng Y, Shi T, Krilis SA: Effect of beta2-glycoprotein I null mutation on reproductive outcome and antiphospholipid antibody-mediated pregnancy pathology in mice. Mol Hum Reprod 2004; 10:409-416.
9. Chamley LW, Allen JL, Johnson PM: Synthesis of beta2 glycoprotein 1 by the human placenta. Placenta 1997; 18:403-410.
10. Backos M, Rai R, Baxter N, Chilcott IT, Cohen H, Regan L: Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin. Br J Obstet Gynaecol 1999; 106:102-107.
11. Branch DW, Khamashta MA: Antiphospholipid syndrome: obstetric diagnosis, management, and controversies. Obstet Gynecol 2003; 101:1333-1344.
12. de Jesus GR, Rodrigues G, de Jesus NR, Levy RA: Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment? Curr Rheumatol Rep 2014; 16:403.
13. Berman J, Girardi G, Salmon JE: TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol 2005; 174:485-490.
14. Girardi G, Berman J, Redecha P, Spruce L, Thurman JM, Kraus D, Hollmann TJ, Casali P, Caroll MC, Wetsel RA, Lambris JD, Holers VM, Salmon JE: Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003; 112:1644-1654.
15. Mulla MJ, Brosens JJ, Chamley LW, Giles I, Pericleous C, Rahman A, Joyce SK, Panda B, Paidas MJ, Abrahams VM: Antiphospholipid antibodies induce a pro-inflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway. Am J Reprod Immunol 2009; 62:96-111.
16. Redecha P, Tilley R, Tencati M, Salmon JE, Kirchhofer D, Mackman N, Girardi G: Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood 2007; 110:2423-2431.
17. Van Horn JT, Craven C, Ward K, Branch DW, Silver RM: Histologic features of placentas and abortion specimens from women with antiphospholipid and antiphospholipid-like syndromes. Placenta 2004; 25:642-648.
18. Bose P, Kadyrov M, Goldin R, Hahn S, Backos M, Regan L, Huppertz B: Aberrations of early trophoblast differentiation predispose to pregnancy failure: lessons from the anti-phospholipid syndrome. Placenta 2006; 27:869-875.
19. Mulla MJ, Myrtolli K, Brosens JJ, Chamley LW, Kwak-Kim JY, Paidas MJ, Abrahams VM: Antiphospholipid Antibodies Limit Trophoblast Migration by Reducing IL-6 Production and STAT3 Activity. Am J Reprod Immunol 2010; 63:339-348.
20. Sebire NJ, Fox H, Backos M, Rai R, Paterson C, Regan L: Defective endovascular trophoblast invasion in primary antiphospholipid antibody syndrome-associated early pregnancy failure. Hum Reprod 2002; 17:1067-1071.
21. Mulla MJ, Salmon JE, Chamley LW, Brosens JJ, Boeras CM, Kavathas PB, Abrahams VM: A Role for Uric Acid and the Nalp3 Inflammasome in Antiphospholipid Antibody-Induced IL-1beta Production by Human First Trimester Trophoblast. PLoS ONE 2013; 8:e65237.
22. Albert CR, Schlesinger WJ, Viall CA, Mulla MJ, Brosens JJ, Chamley LW, Abrahams VM: Effect of hydroxychloroquine on antiphospholipid antibody-induced changes in first trimester trophoblast function. Am J Reprod Immunol 2014; 71:154-164.
23. Han CS, Mulla MJ, Brosens JJ, Chamley LW, Paidas MJ, Lockwood CJ, Abrahams VM: Aspirin and heparin effect on basal and antiphospholipid antibody modulation of trophoblast function. Obstet Gynecol 2011; 118:1021-1028.
24. Odiari EA, Mulla MJ, Sfakianaki AK, Paidas MJ, Stanwood NL, Gariepy A, Brosens JJ, Chamley LW, Abrahams VM: Pravastatin does not prevent antiphospholipid antibody-mediated changes in human first trimester trophoblast function. Hum Reprod 2012; 27:2933-2940.
25. Carroll TY, Mulla MJ, Han CS, Brosens JJ, Chamley LW, Giles I, Pericleous C, Rahman A, Sfakianaki AK, Paidas MJ, Abrahams VM: Modulation of trophoblast angiogenic factor secretion by antiphospholipid antibodies is not reversed by heparin. Am J Reprod Immunol 2011; 66:286-296.
26. Cohn DM, Goddijn M, Middeldorp S, Korevaar JC, Dawood F, Farquharson RG: Recurrent miscarriage and antiphospholipid antibodies: prognosis of subsequent pregnancy. J Thromb Haemost 2010; 8:2208-2213.
27. Stephenson MD, Ballem PJ, Tsang P, Purkiss S, Ensworth S, Houlihan E, Ensom MH: Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. J Obstet Gynaecol Can 2004; 26:729-734.
28. Farquharson RG, Quenby S, Greaves M: Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002; 100:408-413.
29. Girardi G, Redecha P, Salmon JE: Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004; 10:1222-1226.
30. Inbar O, Blank M, Faden D, Tincani A, Lorber M, Shoenfeld Y: Prevention of fetal loss in experimental antiphospholipid syndrome by low-molecular-weight heparin. Am J Obstet Gynecol 1993; 169:423-426.
31. Laskin CA, Spitzer KA, Clark CA, Crowther MR, Ginsberg JS, Hawker GA, Kingdom JC, Barrett J, Gent M: Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol 2009; 36:279-287.
32. Di Simone N, Caliandro D, Castellani R, Ferrazzani S, De Carolis S, Caruso A: Low-molecular weight heparin restores in-vitro trophoblast invasiveness and differentiation in presence of immunoglobulin G fractions obtained from patients with antiphospholipid syndrome. Hum Reprod 1999; 14:489-495.
33. Di Simone N, Ferrazzani S, Castellani R, De Carolis S, Mancuso S, Caruso A: Heparin and low-dose aspirin restore placental human chorionic gonadotrophin secretion abolished by antiphospholipid antibody-containing sera. Hum Reprod 1997; 12:2061-2065.
34. Bose P, Black S, Kadyrov M, Weissenborn U, Neulen J, Regan L, Huppertz B: Heparin and aspirin attenuate placental apoptosis in vitro: implications for early pregnancy failure. Am J Obstet Gynecol 2005; 192:23-30.
35. Drewlo S, Levytska K, Sobel M, Baczyk D, Lye SJ, Kingdom JC: Heparin promotes soluble VEGF receptor expression in human placental villi to impair endothelial VEGF signaling. J Thromb Haemost 2011; 9:2486-2497.
36. Rosenberg VA, Buhimschi IA, Lockwood CJ, Paidas MJ, Dulay AT, Ramma W, Abdel-Razeq SS, Zhao G, Ahmad S, Ahmed A, Buhimschi CS: Heparin elevates circulating soluble fms-like tyrosine kinase-1 immunoreactivity in pregnant women receiving anticoagulation therapy. Circulation 2011; 124:2543-2553.
37. Sela S, Natanson-Yaron S, Zcharia E, Vlodavsky I, Yagel S, Keshet E: Local retention versus systemic release of soluble VEGF receptor-1 are mediated by heparin-binding and regulated by heparanase. Circ Res 2011; 108:1063-1070.
38. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA: Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111:649-658.
39. Karumanchi SA, Stillman IE: In vivo rat model of preeclampsia. Methods Mol Med 2006; 122:393-399.
40. White JH: Vitamin D signaling, infectious diseases, and regulation of innate immunity. Infect Immun 2008; 76:3837-3843.
41. Liu N, Kaplan AT, Low J, Nguyen L, Liu GY, Equils O, Hewison M: Vitamin D induces innate antibacterial responses in human trophoblasts via an intracrine pathway. Biol Reprod 2009; 80:398-406.
42. Pospechova K, Rozehnal V, Stejskalova L, Vrzal R, Pospisilova N, Jamborova G, May K, Siegmund W, Dvorak Z, Nachtigal P, Semecky V, Pavek P: Expression and activity of vitamin D receptor in the human placenta and in choriocarcinoma BeWo and JEG-3 cell lines. Mol Cell Endocrinol 2009; 299:178-187.
43. Andreoli L, Piantoni S, Dall'Ara F, Allegri F, Meroni PL, Tincani A: Vitamin D and antiphospholipid syndrome. Lupus 2012; 21:736-740.
44. Mok CC: Vitamin D and systemic lupus erythematosus: an update. Expert Rev Clin Immunol 2013; 9:453-463.
45. Aghajafari F, Nagulesapillai T, Ronksley PE, Tough SC, O'Beirne M, Rabi DM: Association between maternal serum 25-hydroxyvitamin D level and pregnancy and neonatal outcomes: systematic review and meta-analysis of observational studies. BMJ 2013; 346:f1169.
46. Tabesh M, Salehi-Abargouei A, Tabesh M, Esmaillzadeh A: Maternal vitamin D status and risk of pre-eclampsia: a systematic review and meta-analysis. J Clin Endocrinol Metab 2013; 98:3165-3173.
47. Wei SQ, Qi HP, Luo ZC, Fraser WD: Maternal vitamin D status and adverse pregnancy outcomes: a systematic review and meta-analysis. J Matern Fetal Neonatal Med 2013; 26:889-899.
48. Ota K, Dambaeva S, Han AR, Beaman K, Gilman-Sachs A, Kwak-Kim J: Vitamin D deficiency may be a risk factor for recurrent pregnancy losses by increasing cellular immunity and autoimmunity. Hum Reprod 2014; 29:208-219.
49. Agmon-Levin N, Blank M, Zandman-Goddard G, Orbach H, Meroni PL, Tincani A, Doria A, Cervera R, Miesbach W, Stojanovich L, Barak V, Porat-Katz BS, Amital H, Shoenfeld Y: Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression. Ann Rheum Dis 2011; 70:145-150.
50. Chamley LW, Konarkowska B, Duncalf AM, Mitchell MD, Johnson PM: Is interleukin-3 important in antiphospholipid antibody-mediated pregnancy failure? Fertil Steril 2001; 76:700-706.
51. Chamley LW, Duncalf AM, Konarkowska B, Mitchell MD, Johnson PM: Conformationally altered beta 2-glycoprotein I is the antigen for anti-cardiolipin autoantibodies. Clin Exp Immunol 1999; 115:571-576.
52. Graham CH, Hawley TS, Hawley RG, MacDougall JR, Kerbel RS, Khoo N, Lala PK: Establishment and characterization of first trimester human trophoblast cells with extended lifespan. Exp Cell Res 1993; 206:204-211.
53. Empson M, Lassere M, Craig JC, Scott JR: Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials. Obstet Gynecol 2002; 99:135-144.
54. Lu F, Longo M, Tamayo E, Maner W, Al-Hendy A, Anderson GD, Hankins GD, Saade GR: The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice. Am J Obstet Gynecol 2007; 196:396 e391-396 e397; discussion 396 e397.
55. Liu NQ, Kaplan AT, Lagishetty V, Ouyang YB, Ouyang Y, Simmons CF, Equils O, Hewison M: Vitamin d and the regulation of placental inflammation. J Immunol 2011; 186:5968-5974.
56. Harant H, Andrew PJ, Reddy GS, Foglar E, Lindley IJ: 1alpha, 25-dihydroxyvitamin D3 and a variety of its natural metabolites transcriptionally repress nuclear-factor-kappaB-mediated interleukin-8 gene expression. Eur J Biochem 1997; 250:63-71.
57. Yu XP, Bellido T, Manolagas SC: Down-regulation of NF-kappa B protein levels in activated human lymphocytes by 1, 25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 1995; 92:10990-10994.
58. Evans KN, Nguyen L, Chan J, Innes BA, Bulmer JN, Kilby MD, Hewison M: Effects of 25-hydroxyvitamin D3 and 1, 25-dihydroxyvitamin D3 on cytokine production by human decidual cells. Biol Reprod 2006; 75:816-822.
59. Torry DS, Leavenworth J, Chang M, Maheshwari V, Groesch K, Ball ER, Torry RJ: Angiogenesis in implantation. J Assist Reprod Genet 2007; 24:303-315.
60. Cuadrado MJ, Buendia P, Velasco F, Aguirre MA, Barbarroja N, Torres LA, Khamashta M, Lopez-Pedrera C: Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome. J Thromb Haemost 2006; 4:2461-2469.
61. Williams FM, Parmar K, Hughes GR, Hunt BJ: Systemic endothelial cell markers in primary antiphospholipid syndrome. Thromb Haemost 2000; 84:742-746.
62. Smadja D, Gaussem P, Roncal C, Fischer AM, Emmerich J, Darnige L: Arterial and venous thrombosis is associated with different angiogenic cytokine patterns in patients with antiphospholipid syndrome. Lupus 2010; 19:837-843.
63. Hladunewich M, Karumanchi SA, Lafayette R: Pathophysiology of the clinical manifestations of preeclampsia. Clin J Am Soc Nephrol 2007; 2:543-549.
64. Vaisbuch E, Whitty JE, Hassan SS, Romero R, Kusanovic JP, Cotton DB, Sorokin Y, Karumanchi SA: Circulating angiogenic and antiangiogenic factors in women with eclampsia. Am J Obstet Gynecol 2011; 204:e151-e159.
65. Tsatsaris V, Goffin F, Munaut C, Brichant JF, Pignon MR, Noel A, Schaaps JP, Cabrol D, Frankenne F, Foidart JM: Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 2003; 88:5555-5563.
66. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, Stillman IE, Roberts D, D'Amore PA, Epstein FH, Sellke FW, Romero R, Sukhatme VP, Letarte M, Karumanchi SA: Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12:642-649.
67. Woodham PC, Brittain JE, Baker AM, Long DL, Haeri S, Camargo CA Jr, Boggess KA, Stuebe AM: Midgestation maternal serum 25-hydroxyvitamin D level and soluble fms-like tyrosine kinase 1/placental growth factor ratio as predictors of severe preeclampsia. Hypertension 2011; 58:1120-1125.
68. Grundmann M, Haidar M, Placzko S, Niendorf R, Darashchonak N, Hubel CA, von Versen-Hoynck F: Vitamin D improves the angiogenic properties of endothelial progenitor cells. Am J Physiol Cell Physiol 2012; 303:C954-C962.
69. Al-Ani B, Hewett PW, Cudmore MJ, Fujisawa T, Saifeddine M, Williams H, Ramma W, Sissaoui S, Jayaraman PS, Ohba M, Ahmad S, Hollenberg MD, Ahmed A: Activation of proteinase-activated receptor 2 stimulates soluble vascular endothelial growth factor receptor 1 release via epidermal growth factor receptor transactivation in endothelial cells. Hypertension 2010; 55:689-697.
70. Cardus A, Panizo S, Encinas M, Dolcet X, Gallego C, Aldea M, Fernandez E, Valdivielso JM: 1, 25-dihydroxyvitamin D3 regulates VEGF production through a vitamin D response element in the VEGF promoter. Atherosclerosis 2009; 204:85-89.